Although stem cell therapy has always been a controversial topic, as the general public has gained more knowledge about the practice and induced pluripotent stem (iPS) cells have gained traction in place of human embryonic stem (hES) cells, the conversation has shifted. From ethical concerns to logistical concerns.
Governments, medical facilities and patients are concerned about the economic viability and clinical efficacy of regenerative medicine and stem cell research. Today, six of the seven leading causes of death in America are noncommunicable diseases, and regenerative medicine is a promising branch of science to lead the fight.
A recent study, conducted in 2021, highlights the cost-effectiveness of regenerative medicine. Looking at a handful of stem cell therapies, studies have shown that regenerative medicine can be more cost-effective than other conventional health technologies. The study also noted that for stem cell treatment of scoliosis, the level of cost-effectiveness was acceptable to policymakers and healthcare purchasers.
It is also important to note that the best treatments for patients are those that reduce pain while avoiding dangerous procedures such as surgery. As such, autologous cell therapy falls into this category because the treatment comes from the patient’s own body and the risks are significantly reduced.
Even with reduced treatment risks, the question of clinical efficacy still remains. How successful is stem cell therapy compared to traditional treatments? Research is showing promising results for stem cell therapy in obesity-related diseases and chronic back pain, among other non-communicable diseases.
Current non-operative and surgical treatments for chronic low back pain continue to leave patients unsatisfied, whereas stem cell regenerative therapy has shown strong results in restoring the cellularity of the disc and reducing the inflammatory response in patients. With chronic low back pain affecting an estimated 632 million people worldwide and 68% of adults over the age of 60, finding a cure that minimizes risk and maximizes results will revolutionize treatment.
Stem cells have also shown significant therapeutic potential in patients with diabetes, one of the most prevalent and fatal diseases worldwide. From stem cell therapies capable of regenerating insulin-producing cells to therapies that can stimulate metabolism, the field is ripe with opportunities for patients.
Biorestorative improvements in chronic pain and diabetes
Biorestorative Therapies Inc. BRTX (“BioRestorative”) is working on a product that could be a solution to a multi-billion dollar case. Trials suggest that BRTX-100 can significantly reduce back pain and increase function in patients. More than 60 million sufferers of chronic back pain in the United States Although the current product specifically treats disc degeneration, Biorestorative believes it shows signs of broader application within the entire musculoskeletal system (hips, knees, shoulders and limbs).
Biorestorative therapy prides itself on working properly. Its BRTX100 product for back pain goes beyond the very common clinical practice of harvesting cells and reintroducing them to the patient without proper modification.
Instead, biorestorative therapies expand and culture cells using a proprietary hypoxic treatment, where a low-oxygen environment transforms the cells to reveal more potent therapeutic benefits. They combine these cells with the patient’s own platelet lysate, which acts as a fertilizer for the cells and helps deliver more surviving cells to the disc’s harsh environment. These cells not only have higher survival rates but also show increased anti-inflammatory properties, increased circulation, and improved remodeling of the disc’s extracellular matrix. It uses only autologous cells for this treatment. Autologous cells come from the patient’s own body and the body does not have a low risk of rejecting them, increasing the possibility of optimal results in the process of matching the biological microenvironment.
BRTX has very promising results in the treatment of brown fat programs, thermostats, obesity and related metabolic diseases. Obesity affects 40% of Americans, and BioRestorative is developing a novel stem-cell population — brown adipose tissue — that shows signs of stimulating metabolism and reducing excess fat.
Close collaboration with the FDA is also important to BioRestorative, as external oversight serves as a guarantor of product quality and efficacy. FDA approval also helps reduce the cost of these therapies for patients, as insurance companies are willing to partially or fully cover the cost of FDA-approved drugs.
To learn more about BioRestorative, visit its website.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended as investment advice.
Photo by National Cancer Institute on Splash